JP2014518216A - ヒアルロナン分解酵素の安定な製剤 - Google Patents

ヒアルロナン分解酵素の安定な製剤 Download PDF

Info

Publication number
JP2014518216A
JP2014518216A JP2014516067A JP2014516067A JP2014518216A JP 2014518216 A JP2014518216 A JP 2014518216A JP 2014516067 A JP2014516067 A JP 2014516067A JP 2014516067 A JP2014516067 A JP 2014516067A JP 2014518216 A JP2014518216 A JP 2014518216A
Authority
JP
Japan
Prior art keywords
exactly
insulin
composition
concentration
inclusive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014516067A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014518216A5 (https=
Inventor
ツォン−ホーン・ヤン
マイケル・ジェイムズ・ラバール
ダニエル・エドワード・ボーン
クリストファー・エル・キャスター
フランソワ・ニコル
キム・ドンヒョン
Original Assignee
ハロザイム インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハロザイム インコーポレイテッド filed Critical ハロザイム インコーポレイテッド
Publication of JP2014518216A publication Critical patent/JP2014518216A/ja
Publication of JP2014518216A5 publication Critical patent/JP2014518216A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014516067A 2011-06-17 2012-06-15 ヒアルロナン分解酵素の安定な製剤 Pending JP2014518216A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161520962P 2011-06-17 2011-06-17
US61/520,962 2011-06-17
PCT/US2012/042816 WO2012174478A2 (en) 2011-06-17 2012-06-15 Stable formulations of a hyaluronan-degrading enzyme

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2016200761A Division JP6224802B2 (ja) 2011-06-17 2016-10-12 ヒアルロナン分解酵素の安定な製剤
JP2017111643A Division JP2017197556A (ja) 2011-06-17 2017-06-06 ヒアルロナン分解酵素の安定な製剤

Publications (2)

Publication Number Publication Date
JP2014518216A true JP2014518216A (ja) 2014-07-28
JP2014518216A5 JP2014518216A5 (https=) 2015-07-23

Family

ID=46513830

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014516067A Pending JP2014518216A (ja) 2011-06-17 2012-06-15 ヒアルロナン分解酵素の安定な製剤
JP2016200761A Active JP6224802B2 (ja) 2011-06-17 2016-10-12 ヒアルロナン分解酵素の安定な製剤
JP2017111643A Pending JP2017197556A (ja) 2011-06-17 2017-06-06 ヒアルロナン分解酵素の安定な製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016200761A Active JP6224802B2 (ja) 2011-06-17 2016-10-12 ヒアルロナン分解酵素の安定な製剤
JP2017111643A Pending JP2017197556A (ja) 2011-06-17 2017-06-06 ヒアルロナン分解酵素の安定な製剤

Country Status (13)

Country Link
EP (1) EP2720712B1 (https=)
JP (3) JP2014518216A (https=)
KR (2) KR101874401B1 (https=)
CN (2) CN105797140B (https=)
AU (2) AU2012271359B2 (https=)
BR (1) BR112013032396A2 (https=)
CA (1) CA2839511C (https=)
EA (2) EA201400031A1 (https=)
ES (1) ES2566549T3 (https=)
IL (1) IL229749A0 (https=)
MX (1) MX340172B (https=)
NZ (2) NZ618331A (https=)
WO (1) WO2012174478A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018138578A (ja) * 2014-12-16 2018-09-06 イーライ リリー アンド カンパニー 即効型インスリン組成物
JP2022525883A (ja) * 2019-03-15 2022-05-20 イーライ リリー アンド カンパニー 保存製剤
JP2024501721A (ja) * 2020-12-30 2024-01-15 上海宝済薬業股▲ふん▼有限公司 組換えヒトヒアルロニダーゼ製剤およびその用途

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2451437T3 (pl) 2009-07-06 2017-05-31 Sanofi-Aventis Deutschland Gmbh Wodne preparaty insuliny zawierające metioninę
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
EP3130347B1 (en) 2011-12-30 2019-09-18 Halozyme, Inc. Ph20 polypeptide variants, formulations and uses thereof
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HK1211232A1 (en) 2012-12-21 2016-05-20 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
RU2019128331A (ru) * 2013-02-04 2019-12-16 Санофи Стабилизированные фармацевтические составы аналогов инсулина и/или производные инсулина
TWI780236B (zh) * 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
AR098168A1 (es) * 2013-10-25 2016-05-04 Sanofi Sa Formulación estable de insulina glulisina
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
CN105960249B (zh) 2014-01-09 2021-03-16 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
WO2015145860A1 (ja) * 2014-03-28 2015-10-01 テルモ株式会社 生体血管内血液置換用液体、生体血管内血液置換用液体製剤およびプレフィルドシリンジ
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
CN104095871A (zh) * 2014-07-10 2014-10-15 青岛蔚蓝生物股份有限公司 一种含盐酸林可霉素与硫酸大观霉素的兽用注射液
EP3169351B1 (en) * 2014-07-16 2020-02-26 New York University Use of hyaluronidase for treatment of muscle stiffness
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
CN105018457A (zh) * 2015-07-20 2015-11-04 宁波美成生物科技有限公司 虫荧光素酶稳定剂
CN108699120B (zh) * 2015-11-16 2022-05-13 Ubi蛋白公司 用于延长蛋白质半衰期的方法
JP6798030B2 (ja) 2016-09-06 2020-12-09 シンファー ティアン−リー ファーマシューティカル カンパニー リミテッド（ハンツォウ）Ｓｉｎｐｈａｒ Ｔｉａｎ−Ｌｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． （Ｈａｎｇｚｈｏｕ） 皮膚ケアおよび／または創傷治癒促進における松塊抽出物およびその有効成分の使用
BR112019004935A2 (pt) 2016-09-13 2019-06-04 Allergan, Inc. composições de toxina clostridial não proteíca estabilizada
CN108070532A (zh) * 2016-11-16 2018-05-25 福建力多利生物科技有限公司 一种生产葡萄糖氧化酶的方法
US11510967B2 (en) 2017-09-08 2022-11-29 Eli Lilly And Company Pharmaceutical combinations comprising insulin and at least an agent selected from meloxicam, bromfenac sodium, acetylsalicylic acid, salicyclic acid and paracetamol
CN107918020B (zh) * 2017-11-15 2019-01-01 浙江夸克生物科技有限公司 中性粒细胞明胶酶相关脂质运载蛋白测定试剂盒
EP3636752A4 (en) 2018-07-25 2021-04-28 Alteogen, Inc. NEW HYALURONIC ACID HYDROLYZING ENZYMUTANTS AND THE PHARMACEUTICAL COMPOSITION CONTAINING THIS
MY204342A (en) 2019-03-25 2024-08-24 Alteogen Inc Pharmaceutical composition, comprising human hyaluronidase ph20 variant and drug, for subcutaneous injection
CN110592056A (zh) * 2019-09-19 2019-12-20 昆明理工大学 噬菌体裂解酶复合粉剂及其制备方法和应用
CN110713983B (zh) * 2019-11-04 2022-06-10 深圳市体内生物医药科技有限公司 一种表达透明质酸酶的免疫细胞及其应用
EP3992285A4 (en) * 2020-01-23 2023-01-25 Alteogen, Inc. NOVEL HYALURONIC HYDROLYZING ENZYME VARIANT WITH IMPROVED STABILITY AND PHARMACEUTICAL COMPOSITION CONTAINING IT
JP7622088B2 (ja) 2020-08-07 2025-01-27 アルテオジェン・インコーポレイテッド 組換えヒアルロニダーゼの生産方法
SMT202500208T1 (it) 2020-12-28 2025-07-22 Bristol Myers Squibb Co Composizioni anticorpali e metodi per il loro uso
JP2024501029A (ja) 2020-12-28 2024-01-10 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
EP4424301A4 (en) * 2021-10-29 2025-11-19 Alteogen Inc Pharmaceutical composition comprising a human PH20 hyaluronidase and a medicinal product
CN115820766B (zh) * 2021-12-28 2024-11-12 华熙生物科技股份有限公司 一种酶法制备软骨素寡聚糖的方法及软骨素寡聚糖组合物
EP4531916A1 (en) 2022-06-02 2025-04-09 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
AU2023408268A1 (en) * 2022-12-23 2025-07-10 Hanmi Pharm. Co., Ltd. Formulations comprising immune stimulating IL-2 analog conjugates
KR102554775B1 (ko) * 2023-02-07 2023-07-12 한국코러스 주식회사 히알루로니다제의 안정화제 및 이를 포함하는 히알루로니다제 제형
CN117243852A (zh) * 2023-11-01 2023-12-19 华熙生物科技股份有限公司 一种皮肤外用组合物及其用途
CN119074669B (zh) * 2024-06-21 2025-04-18 邢珺月 一种靶向缓解化疗心脏毒性的纳米酶及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60233018A (ja) * 1984-04-18 1985-11-19 アイ・エム・イー　インタームド　エンタープライセス　ソシエテ・アノニム 尋常性▲ざ▼瘡治療用インシユリン製剤
WO2008016729A1 (en) * 2006-08-04 2008-02-07 Nastech Pharmaceutical Company Inc. Compositions for intranasal delivery of human insulin and uses thereof
WO2009047766A2 (en) * 2007-10-11 2009-04-16 Muhammad Abdulrazik Composition and method for the treatment or prevention of glaucoma and ocular hypertension
WO2009134380A2 (en) * 2008-04-28 2009-11-05 Halozyme, Inc. Super fast-acting insulin compositions

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
EP0250119A3 (en) * 1986-06-20 1990-04-18 Vasocor Atherosclerotic anti-idiotype antibody immunoassay and reagents
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US6093563A (en) 1994-07-08 2000-07-25 Ibex Technologies R And D, Inc. Chondroitin lyase enzymes
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5747027A (en) 1995-04-07 1998-05-05 The Regents Of The University Of California BH55 hyaluronidase
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6610292B2 (en) * 1995-11-22 2003-08-26 Ista Pharmaceuticals, Inc. Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
CA2309955A1 (en) 1997-11-12 1999-05-20 Alza Corporation Method for decreasing self-association of polypeptides
US6669663B1 (en) * 1999-04-30 2003-12-30 Medtronic, Inc. Closed loop medicament pump
US6563022B2 (en) * 1999-07-05 2003-05-13 Toyo Boseki Kabushiki Kaisha Cotton plants with improved cotton fiber characteristics and method for producing cotton fibers from these cotton plants
AU781839B2 (en) 1999-12-22 2005-06-16 Nektar Therapeutics Sterically hindered derivatives of water soluble polymers
AU2001255675B2 (en) * 2000-05-19 2005-04-14 Alcon, Inc. Disulfide derivatives useful for treating allergic diseases
US6902548B1 (en) * 2001-03-19 2005-06-07 Ed Schuler Use of Streptomyces hyalurolyticus enzyme in ophthalmic treatments
US20030125234A1 (en) * 2001-12-11 2003-07-03 Middaugh Charles Russell Alteration of protein stability
WO2004075923A2 (en) 2003-02-26 2004-09-10 Nektar Therapeutics Al, Corporation Polymer-factor viii moiety conjugates
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
ES2532399T3 (es) 2003-03-05 2015-03-26 Halozyme, Inc. Glicoproteína hialuronidasa soluble (sHASEGP), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden
EP1620553A4 (en) * 2003-04-23 2007-01-03 Hexima Ltd INSECT CHYMOTRYPSIN AND INHIBITORS THEREOF
DE602005014962D1 (de) 2004-03-12 2009-07-30 Biodel Inc Insulinzusammensetzungen mit verbesserter wirkstoffabsorption
AU2005227757C1 (en) * 2004-03-31 2009-08-13 Hexima Ltd Arabinogalactan protein compositions and methods for fostering somatic embryogenic competence
WO2005118799A1 (en) * 2004-04-15 2005-12-15 Ista Pharmaceuticals, Inc. Ovine hyaluronidase
WO2007047242A2 (en) * 2005-10-14 2007-04-26 Soll David B Ophthalmic surgical irrigating solutions containing hyaluronidase
JP2009512709A (ja) * 2005-10-20 2009-03-26 エムディーアールエヌエー，インコーポレイテッド 速効型インスリンの経鼻投与
KR20140130512A (ko) 2008-03-06 2014-11-10 할로자임, 아이엔씨 가용성 히알루로니다아제의 대규모 제조
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
CN103205407B (zh) 2008-12-09 2016-03-16 哈洛齐梅公司 延长的可溶性ph20多肽及其用途
PL2451437T3 (pl) * 2009-07-06 2017-05-31 Sanofi-Aventis Deutschland Gmbh Wodne preparaty insuliny zawierające metioninę
MX2012003282A (es) 2009-09-17 2012-04-30 Baxter Healthcare Sa Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso.
JP5890516B2 (ja) * 2011-06-17 2016-03-22 ハロザイム インコーポレイテッド ヒアルロナン分解酵素を用いる連続的皮下インスリン注入方法
EP3130347B1 (en) * 2011-12-30 2019-09-18 Halozyme, Inc. Ph20 polypeptide variants, formulations and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60233018A (ja) * 1984-04-18 1985-11-19 アイ・エム・イー　インタームド　エンタープライセス　ソシエテ・アノニム 尋常性▲ざ▼瘡治療用インシユリン製剤
WO2008016729A1 (en) * 2006-08-04 2008-02-07 Nastech Pharmaceutical Company Inc. Compositions for intranasal delivery of human insulin and uses thereof
WO2009047766A2 (en) * 2007-10-11 2009-04-16 Muhammad Abdulrazik Composition and method for the treatment or prevention of glaucoma and ocular hypertension
WO2009134380A2 (en) * 2008-04-28 2009-11-05 Halozyme, Inc. Super fast-acting insulin compositions
JP2011523940A (ja) * 2008-04-28 2011-08-25 ハロザイム インコーポレイテッド 超速効型インスリン組成物

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018138578A (ja) * 2014-12-16 2018-09-06 イーライ リリー アンド カンパニー 即効型インスリン組成物
JP2021073187A (ja) * 2014-12-16 2021-05-13 イーライ リリー アンド カンパニー 即効型インスリン組成物
JP7093669B2 (ja) 2014-12-16 2022-06-30 イーライ リリー アンド カンパニー 即効型インスリン組成物
JP7159277B2 (ja) 2014-12-16 2022-10-24 イーライ リリー アンド カンパニー 即効型インスリン組成物
JP2022525883A (ja) * 2019-03-15 2022-05-20 イーライ リリー アンド カンパニー 保存製剤
JP2023123742A (ja) * 2019-03-15 2023-09-05 イーライ リリー アンド カンパニー 保存製剤
JP7728176B2 (ja) 2019-03-15 2025-08-22 イーライ リリー アンド カンパニー 保存製剤
JP2024501721A (ja) * 2020-12-30 2024-01-15 上海宝済薬業股▲ふん▼有限公司 組換えヒトヒアルロニダーゼ製剤およびその用途

Also Published As

Publication number Publication date
WO2012174478A2 (en) 2012-12-20
JP6224802B2 (ja) 2017-11-01
EA201400031A1 (ru) 2014-07-30
KR20140043438A (ko) 2014-04-09
MX340172B (es) 2016-06-28
CA2839511C (en) 2018-07-31
IL229749A0 (en) 2014-01-30
EP2720712B1 (en) 2016-03-02
ES2566549T3 (es) 2016-04-13
EA033472B1 (ru) 2019-10-31
JP2017036313A (ja) 2017-02-16
AU2012271359A1 (en) 2014-01-09
NZ717728A (en) 2016-04-29
MX2013014923A (es) 2014-02-11
JP2017197556A (ja) 2017-11-02
KR101874401B1 (ko) 2018-07-04
WO2012174478A9 (en) 2013-05-30
EP2720712A2 (en) 2014-04-23
CN103974715A (zh) 2014-08-06
CA2839511A1 (en) 2012-12-20
BR112013032396A2 (pt) 2016-11-22
AU2016202472B2 (en) 2017-02-02
EA201501068A1 (ru) 2016-07-29
WO2012174478A3 (en) 2013-04-11
CN105797140B (zh) 2020-08-11
KR20170116173A (ko) 2017-10-18
NZ618331A (en) 2016-04-29
CN105797140A (zh) 2016-07-27
AU2012271359B2 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
JP6224802B2 (ja) ヒアルロナン分解酵素の安定な製剤
US9993529B2 (en) Stable formulations of a hyaluronan-degrading enzyme
JP5890516B2 (ja) ヒアルロナン分解酵素を用いる連続的皮下インスリン注入方法
CN102083458B (zh) 超速效胰岛素组合物
NZ618301B2 (en) Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme
HK1150967B (en) Super fast-acting insulin compositions
HK1195728B (en) Super fast-acting insulin compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150604

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160412

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161012

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170207